Pancreatic Adenocarcinoma, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology

2021 Journal of the National Comprehensive Cancer Network 1,146 citations

Abstract

Pancreatic cancer is the fourth leading cause of cancer-related death among men and women in the United States. A major challenge in treatment remains patients’ advanced disease at diagnosis. The NCCN Guidelines for Pancreatic Adenocarcinoma provides recommendations for the diagnosis, evaluation, treatment, and follow-up for patients with pancreatic cancer. Although survival rates remain relatively unchanged, newer modalities of treatment, including targeted therapies, provide hope for improving patient outcomes. Sections of the manuscript have been updated to be concordant with the most recent update to the guidelines. This manuscript focuses on the available systemic therapy approaches, specifically the treatment options for locally advanced and metastatic disease.

Keywords

MedicinePancreatic cancerAdenocarcinomaOncologyDiseaseInternal medicineIntensive care medicineCancerClinical PracticeModalitiesSystemic therapyClinical OncologyGeneral surgeryFamily medicine

Affiliated Institutions

Related Publications

Publication Info

Year
2021
Type
article
Volume
19
Issue
4
Pages
439-457
Citations
1146
Access
Closed

External Links

Social Impact

Social media, news, blog, policy document mentions

Citation Metrics

1146
OpenAlex

Cite This

Margaret A. Tempero, Mokenge P. Malafa, Mahmoud M. Al-Hawary et al. (2021). Pancreatic Adenocarcinoma, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network , 19 (4) , 439-457. https://doi.org/10.6004/jnccn.2021.0017

Identifiers

DOI
10.6004/jnccn.2021.0017